Dermatomyositis - Epidemiology Forecast - 2032

This ‘Dermatomyositis - Epidemiology Forecast - 2032' report delivers an in-depth understanding of Dermatomyositis, historical and forecasted epidemiology, as well as the trends in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.

Dermatomyositis Understanding
Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of connective tissue disorders characterized by progressive muscle weakness. IIM is the umbrella term that includes Dermatomyositis, polymyositis (PM), overlap myositis (OM), sporadic inclusion body myositis (IBM), and necrotizing autoimmune myopathy (NAM), also known as immune-mediated necrotizing myopathy (IMNM).

Dermatomyositis is a rare autoimmune disorder characterized by muscle inflammation (myositis) and skin inflammation (dermatitis). Proximal muscle weakness is a hallmark feature, affecting muscles close to the trunk, such as those in the thighs and upper arms, including heliotrope rash (purplish discoloration around the eyes), Gottron's papules (reddish bumps on knuckles), and photosensitive rash on sun-exposed areas.

Furthermore, Dermatomyositis is a complex and heterogeneous condition that occurs in adults and even children, juvenile Dermatomyositis (JDM). They share the hallmark features of pathognomic skin rash and muscle inflammation but are heterogeneous disorders with various additional features and complications.

Dermatomyositis Diagnosis

The diagnosis of Dermatomyositis involves a combination of clinical evaluation, detection of characteristic physical findings, certain laboratory tests, and imaging studies. Key diagnostic criteria include muscle weakness, characteristic skin rash, elevated muscle enzymes, myositis-associated enzyme levels, electromyography, and muscle biopsy. Muscle biopsy is the most accurate test to confirm the diagnosis and to exclude other causes of muscle weakness or skin rash. However, choosing the right muscle for a biopsy is crucial to prevent a missing diagnosis. Further, the differential diagnosis includes body myositis, myasthenia gravis, muscular dystrophies, motor neuron disease, neuropathy, and inherited metabolic myopathy.

Continued in the report…..

Dermatomyositis Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of Dermatomyositis, age-specific diagnosed prevalent cases of Dermatomyositis, gender-specific diagnosed prevalent cases of Dermatomyositis, severity-specific diagnosed prevalent cases of Dermatomyositis, chronicity-specific diagnosed prevalent cases of Dermatomyositis, and comorbidity-specific diagnosed prevalent cases of Dermatomyositis in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

Dermatomyositis Detailed Epidemiology Segmentation

• According to the publisher's estimates, in 2022, there were nearly 71,351 total diagnosed prevalent cases of Dermatomyositis in the 7MM, of which nearly 9% were juvenile and 91% were adult. These cases are expected to increase by 2032 during the study period (2019-2032).
• Among the 7MM, the US accounted for approximately 54%, EU4 and the UK for nearly 29%, and Japan for 17% of the total diagnosed prevalent cases of Dermatomyositis in 2022. These cases are expected to increase by 2032.
• In the US, the highest cases were found in the 40-59 age group, followed by the 60-79, 18-39, and 0-17 age groups, while the least cases were for the =80 age group, with nearly 14,524, 12,933, 5,203, 4,117, and 1,489 respectively in 2022. The cases are expected to increase during the study period.
• In 2022, the US accounted for nearly 26,051 female and 12,215 male cases of Dermatomyositis. These cases will change during the study period (2019-2032).
• As per the analysis, there were approximately 2,553 mild and 2,015 moderate to severe diagnosed prevalent cases of Dermatomyositis in the UK in 2022. These cases are subject to change and will increase by 2032.
• According to the publisher's estimates, in 2022, among the total diagnosed prevalent cases of Dermatomyositis in the US, there were nearly 11,480 and 26,786 acute and chronic cases, projected to increase during the study period.
• In Japan, comorbidities-specific diagnosed prevalent cases, including ILD, CVD, cancer malignancy, and others (osteoporosis, dysphagia, Raynaud's syndrome, calcinosis, etc.) accounted for nearly 2,462, 2,206, 511, and 7,269 diagnosed prevalent cases, respectively, in 2022. These cases are expected to change during the study period.

Scope of the Report

• The report covers a descriptive overview of Dermatomyositis, explaining its symptoms, pathophysiology, and various diagnostic approaches.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
• The report assesses the disease risk and burden of Dermatomyositis.
• The report helps recognize the growth opportunities in the 7MM concerning the patient population.
• The report provides the segmentation of the disease epidemiology for the 7MM, the total diagnosed prevalent cases of Dermatomyositis, age-specific diagnosed prevalent cases of Dermatomyositis, gender-specific diagnosed prevalent cases of Dermatomyositis, severity-specific diagnosed prevalent cases of Dermatomyositis, chronicity-specific diagnosed prevalent cases of Dermatomyositis, and comorbidity-specific diagnosed prevalent cases of Dermatomyositis.

Report Highlights

• Ten years forecast of Dermatomyositis
• The 7MM Coverage
• Total diagnosed prevalent cases of Dermatomyositis
• Age-specific diagnosed prevalent cases of Dermatomyositis
• Gender-specific diagnosed prevalent cases of Dermatomyositis
• Severity-specific diagnosed prevalent cases of Dermatomyositis
• Chronicity-specific diagnosed prevalent cases of Dermatomyositis
• Comorbidity-specific diagnosed prevalent cases of Dermatomyositis

Key Questions Answered

• What are the disease risks and burdens of Dermatomyositis?
• What is the historical dermatomyositis patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• What would be the forecasted patient pool of Dermatomyositis at the 7MM level?
• What growth opportunities will be across the 7MM concerning the patient population with Dermatomyositis?
• Which country would have the highest diagnosed prevalent population of Dermatomyositis among the countries mentioned above during the forecast period (2023-2032)?
• At what CAGR is the population expected to grow across the 7MM forecast period (2023-2032)?

Reasons to Buy

The dermatomyositis report will allow the user to:

• Develop business strategies by understanding the trends shaping and driving the 7MM dermatomyositis epidemiology forecast.
• The dermatomyositis epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
• The dermatomyositis epidemiology model developed by the publisher is easy to navigate, interactive with a dashboard, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of Disease by Segmentation
• Factors Driving Growth in a Specific Patient Population

Geographies Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019-2032